Evidence map›Paper›PMID 33371732›Full record

ArticleDiabetes & vascular disease research

Impact of glucagon like peptide-1 receptor agonist and sodium glucose cotransporter 2 inhibitors on type 2 diabetes patients with renal impairment.

Takeyuki Hiramatsu, Hiroki Ito, Shota Okumura, Yuko Asano, Daiki Iguchi, Shinji Furuta

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Diabetes & vascular disease research. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 2 pooled it
1.0field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 2 syntheses or guidelines pooled it, 13 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Takeyuki HiramatsuDepartment of Nephrology, Aichi Welfare Cooperative Agricultural Federation, Konan-Kosei Hospital, Konan, Aichi, Japan.ORCID 0000-0001-7500-600X
Hiroki ItoDepartment of Nephrology, Aichi Welfare Cooperative Agricultural Federation, Konan-Kosei Hospital, Konan, Aichi, Japan.
Shota OkumuraDepartment of Nephrology, Aichi Welfare Cooperative Agricultural Federation, Konan-Kosei Hospital, Konan, Aichi, Japan.
Yuko AsanoDepartment of Nephrology, Aichi Welfare Cooperative Agricultural Federation, Konan-Kosei Hospital, Konan, Aichi, Japan.
Daiki IguchiDepartment of Nephrology, Aichi Welfare Cooperative Agricultural Federation, Konan-Kosei Hospital, Konan, Aichi, Japan.
Shinji FurutaDepartment of Nephrology, Aichi Welfare Cooperative Agricultural Federation, Konan-Kosei Hospital, Konan, Aichi, Japan.
Konan Kosei Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionDiabetes mellitus is a progressive disease with cardiovascular complications. We evaluated the impact of a glucagon like peptide-1 (GLP-1) receptor agonist and sodium glucose cotransporter 2 (SGLT-2) inhibitors dapagliflozin and empagliflozin on renal and cardiac function in type 2 diabetes patients with renal impairment. MATERIALS AND

methodsA total of 156 patients referred with suboptimal glycemic control were assigned to Group G (GLP-1):

resultsCompared with baseline, HbA1c and systolic blood pressure significantly decreased in both groups (

conclusionsThe GLP-1 receptor agonist and SGLT-2 inhibitors were effective for glycemic and blood pressure control and for maintaining renal function. The GLP-1 receptor agonist improved diastolic function at 36 months.

Indexed as

Glucagon-Like Peptide-1 Receptor AgonistsAgedAlbuminuriaBenzhydryl CompoundsBlood GlucoseBlood PressureDiabetes Mellitus, Type 2Diabetic NephropathiesFemaleGlomerular Filtration RateGlucagon-Like Peptide-1 ReceptorGlucosidesHumansIncretinsKidneyLiraglutideBenzhydryl CompoundsBlood GlucosedapagliflozinempagliflozinGLP1R protein, humanGlucagon-Like Peptide-1 ReceptorGlucagon-Like Peptide-1 Receptor AgonistsGlucosidesIncretinsLiraglutideSodium-Glucose Transporter 2 Inhibitorsalbuminuriacardiac diastolic functioneGFRGLP-1 receptor agonistSGLT-2 inhibitor

Identifiers

PMID33371732
PMCPMC7919219
OpenAlexW3116719029

What OpenQuestion holds

Texttitle and abstract
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.